Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms

ABSTRACT Introduction: Cardiovascular and renal disease accounts for a substantial proportion of the morbidity and mortality associated with obesity and type 2 diabetes mellitus (T2DM). Bariatric surgery is associated with improved long-term cardiovascular and renal outcomes. Areas covered: All major case-control, cohort, and randomized controlled trial studies of bariatric surgery in adults with T2DM were screened and data on prespecified cardiovascular and renal outcomes collated. Bariatric surgery reduces all-cause mortality and risk of cardiovascular disease, albuminuria and progressive chronic kidney disease. Patients with poorer glycemic control and established microvascular disease preoperatively may stand to benefit the most from the surgical approach. Reduced sympathetic drive, remission of glomerular hypertension, enhanced natriuresis, gut microbiota shifts, reduced systemic and renal inflammation, improved lipoprotein profiles, and reductions in chronic cardiac remodeling may all be implicated. Expert commentary: Ongoing RCTs of bariatric surgery selectively recruiting patients with class 1 obesity and established microvascular complications of diabetes will help to better characterize which subgroups of patients benefit most from this effective therapy.

[1]  High Density Lipoprotein , 2020, Definitions.

[2]  P. Kimmel,et al.  Effect of Bariatric Surgery on CKD Risk. , 2018, Journal of the American Society of Nephrology : JASN.

[3]  C. Pusey,et al.  Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort , 2018, Scientific Reports.

[4]  B. Wolfe,et al.  Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study , 2017, JAMA surgery.

[5]  C. L. le Roux,et al.  Urinary sodium excretion after gastric bypass surgery. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[6]  D. Carey,et al.  Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long‐Term Risks of Congestive Heart Failure , 2017, Journal of the American Heart Association.

[7]  L. Genser,et al.  Bariatric surgery versus intensive medical therapy for diabetes -5- year outcomes , 2017 .

[8]  Y. Natochin,et al.  Involvement of Glucagon-Like Peptide-1 in the Regulation of Selective Excretion of Sodium or Chloride Ions by the Kidneys , 2017, Bulletin of Experimental Biology and Medicine.

[9]  Deepak L. Bhatt,et al.  Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.

[10]  C. L. le Roux,et al.  Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial , 2017, BMJ Open.

[11]  C. L. le Roux,et al.  Measuring changes in renal function after bariatric surgery: Why estimated glomerular filtration rate is not good enough. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[12]  Pin Zhang,et al.  Effects of Bariatric Surgery on Renal Function in Obese Patients: A Systematic Review and Meta Analysis , 2016, PloS one.

[13]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[14]  D. Ramji,et al.  Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets. , 2016, Future medicinal chemistry.

[15]  M. Sánchez-Niño,et al.  Targeting inflammation in diabetic kidney disease: early clinical trials , 2016, Expert opinion on investigational drugs.

[16]  B. Wolfe,et al.  Type 2 Diabetes Remission Rates After Laparoscopic Gastric Bypass and Gastric Banding: Results of the Longitudinal Assessment of Bariatric Surgery Study , 2016, Diabetes Care.

[17]  Frank B Hu,et al.  Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. , 2016, Circulation research.

[18]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.

[19]  A. Darzi,et al.  The Effects of Bariatric Surgery on Cardiac Structure and Function: a Systematic Review of Cardiac Imaging Outcomes , 2016, Obesity Surgery.

[20]  D. Flum,et al.  Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial , 2016, Diabetologia.

[21]  C. W. Roux,et al.  Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care , 2016, Diabetologia.

[22]  P. Ridker From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[23]  S. Gudbjörnsdottir,et al.  Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. , 2015, The lancet. Diabetes & endocrinology.

[24]  F. Rubino,et al.  Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.

[25]  Fredrik H. Karlsson,et al.  Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation , 2015, Cell metabolism.

[26]  Avis J. Thomas,et al.  Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[27]  J. Tham,et al.  Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery , 2015, Current Cardiology Reports.

[28]  Michael E. Hall,et al.  Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. , 2015, Circulation research.

[29]  L. Rohrer,et al.  Rapid and Body Weight–Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass: Role of Glucagon-Like Peptide-1 , 2015, Circulation.

[30]  Jimmy D Bell,et al.  Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults , 2014, Gut.

[31]  Deepak L. Bhatt,et al.  Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non‐remission status after bariatric surgery , 2014, Diabetes, obesity & metabolism.

[32]  N. Docherty,et al.  Improvements in the metabolic milieu following Roux‐en‐Y gastric bypass and the arrest of diabetic kidney disease , 2014, Experimental physiology.

[33]  A. Ortiz,et al.  Inflammation in Diabetic Kidney Disease , 2018, Nephron.

[34]  S. Saydah,et al.  Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999‐2010 , 2014, Obesity.

[35]  Paul M Ridker,et al.  Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.

[36]  C. Costagliola,et al.  New Insight into Adiponectin Role in Obesity and Obesity-Related Diseases , 2014, BioMed research international.

[37]  C. Bouchard,et al.  Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. , 2014, JAMA.

[38]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.

[39]  Markku Peltonen,et al.  The incidence of albuminuria after bariatric surgery and usual care in swedish obese subjects (SOS): a prospective controlled intervention trial , 2014, International Journal of Obesity.

[40]  M. Carstensen,et al.  Adiponectin and Bariatric Surgery: Associations With Diabetes and Cardiovascular Disease in the Swedish Obese Subjects Study , 2014, Diabetes Care.

[41]  N. Di Daniele,et al.  Obesity, inflammation and endothelial dysfunction. , 2014, Journal of biological regulators and homeostatic agents.

[42]  D. Nathan,et al.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.

[43]  R. Kazancioglu Risk factors for chronic kidney disease: an update , 2013, Kidney international supplements.

[44]  B. Wolfe,et al.  Baseline characteristics of participants in the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. , 2013, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[45]  J. Ortega,et al.  Endothelial dysfunction in morbid obesity. , 2013, Current pharmaceutical design.

[46]  G. Shefer,et al.  Adipose tissue renin–angiotensin–aldosterone system (RAAS) and progression of insulin resistance , 2013, Molecular and Cellular Endocrinology.

[47]  A. Darzi,et al.  Obesity-related cardiorenal disease: the benefits of bariatric surgery , 2013, Nature Reviews Nephrology.

[48]  L. Aronne,et al.  Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. , 2013, Journal of clinical lipidology.

[49]  C. L. le Roux,et al.  Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. , 2013, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[50]  Avis J. Thomas,et al.  Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. , 2013, JAMA.

[51]  M. Pencina,et al.  Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study , 2013, Diabetes Care.

[52]  L. Sjöström Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery , 2013, Journal of internal medicine.

[53]  P. Scherer,et al.  Adiponectin promotes functional recovery after podocyte ablation. , 2013, Journal of the American Society of Nephrology : JASN.

[54]  H. Lönroth,et al.  Gastric Bypass Surgery Is Followed by Lowered Blood Pressure and Increased Diuresis - Long Term Results from the Swedish Obese Subjects (SOS) Study , 2012, PloS one.

[55]  F. Rubino,et al.  Bariatric surgery for type 2 diabetes , 2012, The Lancet.

[56]  S. Rao Inflammatory markers and bariatric surgery: a meta-analysis , 2012, Inflammation Research.

[57]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy in obese patients with diabetes. , 2012, The New England journal of medicine.

[58]  F. Rubino,et al.  Bariatric surgery versus conventional medical therapy for type 2 diabetes. , 2012, The New England journal of medicine.

[59]  H. Kobori,et al.  The Link Between the Renin-Angiotensin-Aldosterone System and Renal Injury in Obesity and the Metabolic Syndrome , 2012, Current Hypertension Reports.

[60]  A. M. Habib,et al.  Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2 , 2012, Diabetes.

[61]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[62]  R. Taub,et al.  Anti-inflammatory therapeutics for the treatment of atherosclerosis , 2011, Nature Reviews Drug Discovery.

[63]  A. Balmforth,et al.  Neprilysin, obesity and the metabolic syndrome , 2010, International Journal of Obesity.

[64]  J. Tap,et al.  Differential Adaptation of Human Gut Microbiota to Bariatric Surgery–Induced Weight Loss , 2010, Diabetes.

[65]  Rodica Pop-Busui,et al.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[66]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[67]  S. Ikramuddin,et al.  Hyperoxaluria is a long-term consequence of Roux-en-Y Gastric bypass: a 2-year prospective longitudinal study. , 2010, Journal of the American College of Surgeons.

[68]  R. Carey,et al.  Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease , 2010, American Journal of Nephrology.

[69]  C. Earthman,et al.  Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. , 2010, Journal of the American Dietetic Association.

[70]  Grant Smith,et al.  Obesity-induced Hypertension: Role of Sympathetic Nervous System, Leptin, and Melanocortins* , 2010, The Journal of Biological Chemistry.

[71]  P. Pellikka,et al.  Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for morbid obesity. , 2010, The American journal of cardiology.

[72]  M. Volpe,et al.  Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. , 2010, Clinical science.

[73]  K. Sharma The link between obesity and albuminuria: adiponectin and podocyte dysfunction. , 2009, Kidney international.

[74]  B. Falkner,et al.  Adiponectin regulates albuminuria and podocyte function in mice. , 2008, The Journal of clinical investigation.

[75]  G. Sweeney,et al.  Cardiac remodeling in obesity. , 2008, Physiological reviews.

[76]  Margaret Anderson,et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[77]  S. Bloom,et al.  Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.

[78]  J. Holst The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[79]  Steven C Hunt,et al.  Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.

[80]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[81]  A. Rule,et al.  Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. , 2007, Kidney international.

[82]  J. Bonet,et al.  Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. , 2006, Journal of the American Society of Nephrology : JASN.

[83]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[84]  Merlin C. Thomas,et al.  Mechanisms of Disease: pathway-selective insulin resistance and microvascular complications of diabetes , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[85]  D. Levy,et al.  Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.

[86]  Steve N Caritis,et al.  Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization , 2004, The New England journal of medicine.

[87]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[88]  A. Huber,et al.  Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. , 2004, The Journal of clinical endocrinology and metabolism.

[89]  John E. Hall,et al.  Chronic Cardiovascular and Renal Actions of Leptin: Role of Adrenergic Activity , 2002, Hypertension.

[90]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[91]  D. Uttenweiler,et al.  Podocytes respond to mechanical stress in vitro. , 2001, Journal of the American Society of Nephrology : JASN.

[92]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[93]  H. Sugerman,et al.  Intra‐abdominal pressure, sagittal abdominal diameter and obesity comorbidity , 1997, Journal of internal medicine.

[94]  A. Donker,et al.  Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus , 1992, The Lancet.

[95]  L. Dworkin,et al.  Does essential hypertension cause end-stage renal disease? , 1992, Kidney international. Supplement.

[96]  USRDS Annual Data Report : Executive Summary , 2019 .

[97]  U. Landmesser,et al.  High-density lipoprotein: Vascular protective effects, dysfunction, and potential as therapeutic target , 2018 .

[98]  Paul Poirier,et al.  Overview of epidemiology and contribution of obesity to cardiovascular disease. , 2014, Progress in cardiovascular diseases.

[99]  H. Kramer,et al.  Obesity and kidney disease: potential mechanisms. , 2013, Seminars in nephrology.

[100]  Christine Maric-Bilkan Obesity and diabetic kidney disease. , 2013, The Medical clinics of North America.

[101]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.

[102]  T. Kurth,et al.  Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). , 2008, American heart journal.

[103]  A. Nitenberg,et al.  Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. , 2006, Diabetes care.

[104]  G. Moneta Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years After Bariatric Surgery , 2006 .

[105]  Steven Hawken,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries , 2004 .

[106]  N. Barnett,et al.  of Medicine , 2004 .